Clinical Trial Update: Efficacy and Safety of UGN-101 in Recurrent Patients [Phase 3]

View source ↗

Summary

Phase 3 trial of UGN-101 for recurrent carcinoma variants has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Transitional Cell Cancer of the Renal Pelvis and Ureter
• Transitional Cell Carcinoma

Drugs mentioned

• UGN-101

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Carcinoma, Transitional Cell Carcinoma | Phase 3 | Status: WITHDRAWN